Key Takeaway: Edwards Lifesciences has expressed satisfaction with the recent national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) issued by CMS. The company views this policy update as a crucial advancement in enhancing patient access to TAVR procedures. Additionally, it emphasizes the importance of a collaborative approach through a multidisciplinary Heart Team in managing aortic stenosis.
Price reaction · baseline $86.77 (2026-09-10 close) · hit after-hours · clean, no other EW news in the window
day 0 close · peak
-2.8%
Market Sentiment Analysis
POSITIVE FACTORS
Updated policy improves patient access to TAVR.
Reinforces the value of a multidisciplinary Heart Team.
Significant step forward for aortic stenosis treatment.
Full Press Release Details
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):“Edwards is pleased that this updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a multidisciplinary Heart Team. Aortic stenosis is a serious, pro
Frequently Asked Questions
What is the TAVR national coverage decision?
The TAVR national coverage decision is a policy update by CMS that affects patient access to transcatheter aortic valve replacement.
How does Edwards Lifesciences view the NCD?
Edwards Lifesciences is pleased with the NCD, seeing it as a significant step to improve patient access to TAVR.
What is the role of a multidisciplinary Heart Team?
The multidisciplinary Heart Team is emphasized as crucial for managing aortic stenosis and ensuring effective treatment.